Lilly Treatment Gets FDA Approval

(Image courtesy of Eli Lilly and Co.)

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says the U.S. Food and Drug Administration has approved Taltz for the treatment of active psoriatic arthritis. The FDA last year approved the injectable treatment for adults with moderate-to-severe plaque psoriasis.

The company says Taltz proved effective and safe during two Phase 3 studies involving more than 670 adult patients. Lilly says results from both studies showed patients treated with Taltz achieved "significant improvement in joint symptoms." The drugmaker says it will work with insurers, providers and health systems to help ensure patients can access the treatment.

Over the summer, Lilly reported second quarter net income of more than $1 billion, compared to $748 million during the same quarter last year, citing in part momentum of new products including Taltz. In October, Lilly reported third quarter net income of $555.6 million, compared to $778 million for the third quarter last year.